Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
企業コードACLX
会社名Arcellx Inc
上場日Feb 04, 2022
最高経営責任者「CEO」Elghandour (Rami)
従業員数163
証券種類Ordinary Share
決算期末Feb 04
本社所在地800 Bridge Parkway
都市REDWOOD CITY
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94065
電話番号12403270603
ウェブサイトhttps://www.arcellx.com/
企業コードACLX
上場日Feb 04, 2022
最高経営責任者「CEO」Elghandour (Rami)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし